CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project 'PATHFINDER' focuses on developing synthetic dendritic cells using flexible polymers to enhance the activation and expansion of tumor-specific T cells for cancer immunotherapy. This innovative approach aims to streamline the production process, making it more efficient and accessible for clinical applicatio…
Cancer immunotherapy and adoptive transfer of genetically manipulated T cells in particular has shown promising results for the treatment of cancer.
Central in cancer immunotherapy is the activation of tumour-specific T cells.
However, the wide-spread clinical use of T cell therapies remains limited due to costly, time-consuming and labour-intensive processes associated with the ex vivo activation and expansion of tumour-specific T cells.
Artificial antigen presenting cells (aAPCs) have been dev…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
